Erratum to: Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study
- PMID: 27832343
- PMCID: PMC6828107
- DOI: 10.1007/s10157-016-1350-0
Erratum to: Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study
Erratum for
-
Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.Clin Exp Nephrol. 2017 Jun;21(3):513-522. doi: 10.1007/s10157-016-1299-z. Epub 2016 Jul 7. Clin Exp Nephrol. 2017. PMID: 27389681 Free PMC article. Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources